Ocugen, Inc. $OCGN

What the company doesAI summary of filing

Ocugen is a clinical-stage biopharmaceutical company developing gene therapies and biologics for retinal diseases and other conditions. The company's lead programs use a modifier gene therapy platform to deliver nuclear hormone receptor genes to treat inherited retinal diseases such as retinitis pigmentosa and Stargardt disease, as well as geographic atrophy associated with dry age-related macular degeneration. OCU400 is in Phase 3 trials for retinitis pigmentosa, while OCU410 and OCU410ST are in Phase 1/2 and Phase 2/3 trials respectively. The company also develops OCU200, a fusion protein therapy for diabetic macular edema and wet age-related macular degeneration, which is in early-stage clinical trials, and maintains a regenerative medicine cell therapy platform. Ocugen is pre-revenue from its primary programs, with product candidates currently in clinical development stages. [10-K 2026-03-04]

Segments: OCU400 (modifier gene therapy for retinitis pigmentosa), OCU410 (modifier gene therapy for geographic atrophy), OCU410ST (modifier gene therapy for Stargardt disease), OCU200 (fusion protein for diabetic macular edema and retinopathy)